Table 2.
List of replicated metabolites positively associated with colorectal cancer1
| Compound Name | ID level2 | Discovery stage: ColoCare Study | Replication stage: CORSA | ||||||
|---|---|---|---|---|---|---|---|---|---|
| CRC Mean ± SD3 | Controls Mean ± SD3 | OR.std 4 [95% CI] | p value5 | CRC Mean ± SD3 | ControlsMean ± SD3 | OR.std 4 [95% CI] | p value5 | ||
| Taurine | 1 | 12.53 ± 0.28 | 12.41 ± 0.24 | 1.44 [1.13; 1.87] | 7.2E‐03 | 12.96 ± 0.49 | 12.66 ± 0.34 | 1.95 [1.53; 2.51] | 4.2E‐06 |
| Hypoxanthine | 1 | 13.18 ± 1.32 | 11.73 ± 0.91 | 3.07 [2.25; 4.45] | 9.1E‐17 | 12.00 ± 0.53 | 11.79 ± 0.49 | 1.43 [1.09; 1.92] | 3.6E‐02 |
| LysoPE(20:4) | 2 | 12.64 ± 0.30 | 12.50 ± 0.26 | 1.37 [1.08; 1.76] | 2.0E‐02 | 12.66 ± 0.32 | 12.51 ± 0.32 | 1.51 [1.15; 2.01] | 1.4E‐02 |
| LysoPE(22:6) | 2 | 12.48 ± 0.40 | 12.21 ± 0.29 | 1.80 [1.42; 2.31] | 1.5E‐06 | 12.41 ± 0.34 | 12.28 ± 0.36 | 1.60 [1.20; 2.17] | 7.8E‐03 |
| 171.0292@2.8578448 | 4 | 10.32 ± 0.52 | 10.04 ± 0.40 | 1.61 [1.26; 2.08] | 3.4E‐04 | 10.2 ± 0.54 | 9.81 ± 0.41 | 2.04 [1.52; 2.81] | 3.5E‐05 |
| 279.1473@2.7668757 | 4 | 11.08 ± 0.83 | 10.59 ± 0.66 | 1.38 [1.09; 1.77] | 1.5E‐02 | 10.64 ± 0.84 | 9.97 ± 0.66 | 2.20 [1.62; 3.08] | 1.0E‐05 |
| 428.3615@7.4910417 | 4 | 9.61 ± 0.34 | 9.49 ± 0.26 | 1.49 [1.07; 2.15] | 3.3E‐02 | 9.56 ± 0.25 | 9.45 ± 0.18 | 1.59 [1.14; 2.26] | 2.8E‐02 |
1
Controls are defined as individuals not diagnosed with any colorectal malignancy.
2
According to MSI.
3
Log transformed relative intensity values.
4
OR.std: standardized Odds Ratio, represents the relative change in colorectal cancer (CRC) risk when there is a one standard deviation (SD) change in metabolite intensity. OR.std is based on the SD of the controls.
5
p‐value: FDR‐corrected p‐value.